Translational pharmacology of (+)-terrein: from biological activity to oral and periodontal therapeutic development
Abstract
Previous terrein reviews have emphasized its isolation, synthesis, production, and broad biological activities. Among the prior reviews identified in the literature, no oral/dental indication-specific critical appraisal was found that integrated chemical comparability, evidence directness, exposure, target engagement, formulation, safety, and reproducibility. The present review therefore critically appraised (+)-terrein as a focused case study in oral translational pharmacology and as a model for examining natural-product drug-development bottlenecks. Terrein-specific literature searches were updated through 14 September 2026 in PubMed/MEDLINE, Scopus, and Web of Science Core Collection. The three database searches identified 411 records; after removal of 160 duplicates, 251 unique records remained. Application of predefined eligibility criteria yielded 61 original studies forming the qualitative evidence base, of which 27 underwent structured in-depth appraisal using explicit author-defined criteria. Recurrent biological activity was reported across multiple experimental contexts and by groups without author overlap with the principal oral/skeletal research network, whereas the integrated oral/skeletal evidence sequence remains concentrated within an overlapping collaborative network. Early studies employed fungus-isolated, racemic, or incompletely comparable preparations, whereas later periodontal and skeletal studies predominantly used synthetic (+)-terrein. Biochemical inhibition of the 20S proteasome has been reported at relatively high concentrations; however, no dominant molecular target has been pharmacologically validated at exposure levels corresponding to the key periodontal cellular models. Formal parent-compound pharmacokinetics, periodontal tissue-exposure data, and a clinically relevant oral/periodontal formulation also remain unavailable. A tumor-targeted nanocarrier study provides proof-of-concept for formulation but does not establish oral exposure or periodontal delivery. Among the indications examined, periodontitis provides the most integrated preclinical sequence, linking responses in human gingival fibroblasts, osteoclast inhibition, and a disease-specific mouse model. In that model, the reduction in micro-CT–assessed alveolar bone resorption did not reach statistical significance, despite significant osteoclast- and TNF-α-related effects; moreover, dosing represented systemic preventive/early intervention rather than local treatment of established disease. Further development therefore requires chemical standardization, exposure–response characterization, orthogonal target validation, an oral/periodontal formulation, indication-specific safety assessment, and replication of the periodontal findings by an independent laboratory. Collectively, the available evidence supports (+)-terrein as an experimental pharmacological and drug-development scaffold rather than as a clinically validated therapy.
Related
- Berberine in Alzheimer’s disease: from TCM pharmacology to translational barriers and multi-target therapeutic development
- A mechanistic quantitative systems pharmacology framework enriched by multiscale data enables model-informed translational development of mesenchymal stem cell therapy in lupus nephritis.
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
- Cannabinoids in oncology: pharmacology, clinical applications, and translational perspectives
- From Biomarker to Trigger: Biological Calibration of Stimuli-Responsive Gels Toward Precision Periodontal Therapy.
BibTeX
@article{omori2026translational,
title = {{Translational pharmacology of (+)-terrein: from biological activity to oral and periodontal therapeutic development}},
author = {Kazuhiro Omori and Hiroki Mandai and Masaaki Nakayama and Tsugumichi Saito and Toshiaki Ohara and Soichiro Ibaragi and Seiji Suga and Shogo Takashiba},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.2010353},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.2010353},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Translational pharmacology of (+)-terrein: from biological activity to oral and periodontal therapeutic development
AU - Kazuhiro Omori
AU - Hiroki Mandai
AU - Masaaki Nakayama
AU - Tsugumichi Saito
AU - Toshiaki Ohara
AU - Soichiro Ibaragi
AU - Seiji Suga
AU - Shogo Takashiba
PY - 2026
DA - 2026/11/03
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.2010353
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.2010353
AB - Previous terrein reviews have emphasized its isolation, synthesis, production, and broad biological activities. Among the prior reviews identified in the literature, no oral/dental indication-specific critical appraisal was found that integrated chemical comparability, evidence directness, exposure, target engagement, formulation, safety, and reproducibility. The present review therefore critically appraised (+)-terrein as a focused case study in oral translational pharmacology and as a model for examining natural-product drug-development bottlenecks. Terrein-specific literature searches were updated through 14 September 2026 in PubMed/MEDLINE, Scopus, and Web of Science Core Collection. The three database searches identified 411 records; after removal of 160 duplicates, 251 unique records remained. Application of predefined eligibility criteria yielded 61 original studies forming the qualitative evidence base, of which 27 underwent structured in-depth appraisal using explicit author-defined criteria. Recurrent biological activity was reported across multiple experimental contexts and by groups without author overlap with the principal oral/skeletal research network, whereas the integrated oral/skeletal evidence sequence remains concentrated within an overlapping collaborative network. Early studies employed fungus-isolated, racemic, or incompletely comparable preparations, whereas later periodontal and skeletal studies predominantly used synthetic (+)-terrein. Biochemical inhibition of the 20S proteasome has been reported at relatively high concentrations; however, no dominant molecular target has been pharmacologically validated at exposure levels corresponding to the key periodontal cellular models. Formal parent-compound pharmacokinetics, periodontal tissue-exposure data, and a clinically relevant oral/periodontal formulation also remain unavailable. A tumor-targeted nanocarrier study provides proof-of-concept for formulation but does not establish oral exposure or periodontal delivery. Among the indications examined, periodontitis provides the most integrated preclinical sequence, linking responses in human gingival fibroblasts, osteoclast inhibition, and a disease-specific mouse model. In that model, the reduction in micro-CT–assessed alveolar bone resorption did not reach statistical significance, despite significant osteoclast- and TNF-α-related effects; moreover, dosing represented systemic preventive/early intervention rather than local treatment of established disease. Further development therefore requires chemical standardization, exposure–response characterization, orthogonal target validation, an oral/periodontal formulation, indication-specific safety assessment, and replication of the periodontal findings by an independent laboratory. Collectively, the available evidence supports (+)-terrein as an experimental pharmacological and drug-development scaffold rather than as a clinically validated therapy.
SN - 1663-9812
ER -